MedTrace Logo

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

NCT01317004 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2015-06-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod

0.5 mg/day oral capsule

DRUG

Standard MS DMT

Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

  • Renato Turrini, MD · Novartis Farma S.p.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317004 on ClinicalTrials.gov